Brand profile · Biotechnology Research

Nuevocor

Nuevocor works in Biotechnology Research, out of Singapore. It is privately held, and its site is nuevocor.com. It holds two addresses on record across two office countries. Headcount on record is 31. One Singapore registration (UEN) is a confirmed match. The latest round on record is Series B at US$45.0M. The record links six similar brands, most of them in Biotechnology Research.

nuevocor.com LinkedIn

Profile live Privately Held Founded 2021 1 entity UEN 2 office countries US$ 45.0M Series B
Registry verified · ACRA
Counted staff
31
self-reported 11–50 band
Founded
2021
5 years
Legal entities
1
ACRA
Office countries
2
2 addresses
Funding rounds
3
Series B · Jun 2025 · US$ 45.0M
Company type
Privately Held
self-reported
Use this profile Compare Your shortlist

Legal entity

1 brand → 1 confirmed entity

Legal entities

Nuevocor: 1 registry entityNuevocor is linked to 1 registry entity: NUEVOCOR PTE. LTD. (UEN 202011115E, confirmed).NuevocorNUEVOCOR PTE. LTD.UEN 202011115EConfirmed · ACRA
Show as table
NUEVOCOR PTE. LTD.UEN 202011115E
Confirmed matches1 of 1

A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.

Description

Nuevocor, with offices in USA and Singapore, is developing genetic medicines for untreatable genetic cardiomyopathies by leveraging insights from our PrOSIA mechanobiology platform.

Locations

2
Countries with an office address2 addresses on record
SingaporeprimaryUnited States

Country footprint

Offices in 2 countriesCountry footprint: 2 countries, primary SG. Codes: SG, US.2 countriesprimary SGSGUS
Show as table
Countries2
Primary countrySG

All codes: SG US

Addresses

  • USPhiladelphia
  • SGSingaporePrimary

Grid intelligence Members

Funding

Last round · 6 June 2025US$ 45.0MSeries B · investors: Angelini Ventures, Kurma Partners
Rounds3
Round typeSeries B · venture round
Amount (USD)45,000,000
Stage rank4
Investors named2
Since last round7 mo

Funding

3 funding roundsFunding timeline. Latest round 6 Jun 2025: Series B, US$ 45.0M.20212026Series BUS$ 45.0M3 rounds
Show as table
Rounds3
Axis2021 to 2026
Series B · 6 Jun 2025US$ 45.0M

Dated rounds only. The axis ends at the date this profile was last observed, not at today.

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Notify me about spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend
Notify me about signals

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
Notify me about financials

People & contacts

4 employee profiles on record · names withheld.

Names are withheld until a consented source exists.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

Which legal entity operates under Nuevocor?

One Singapore entity on ACRA: NUEVOCOR PTE. LTD. (UEN 202011115E), high confidence.

How many people work at Nuevocor?

31 counted staff profiles at January 2026, inside the self-reported 11–50 band.

Where does Nuevocor have offices?

Two addresses on record across 2 countries. Primary: Singapore.

Has Nuevocor raised funding?

Three rounds. Latest 6 June 2025: Series B, US$45,000,000, investors Angelini Ventures and Kurma Partners.

Which companies are listed alongside Nuevocor?

19 profiles list Nuevocor as a peer — 93rd percentile in Biotechnology Research. It lists ten peers of its own. Lerna Biopharma and ClavystBio list it back.

What is Nuevocor's website?

nuevocor.com